Back

Translational rodent models embracing the complex pathophysiology of heart failure with preserved ejection fraction

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - pathophysiology and mechanisms 12 Heart Failure with Preserved Ejection Fraction (HFpEF) HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Rana Assaly

Cardiomedex, Escalquens (France)

5 More presentations in this session

Presentation thumbnail
Implications of sarcopenia and obesity in patients across the spectrum of heart failure with preserved ejection fraction
Doctor P. Sagmeister (Leipzig, DE)
Abstract Slides Video
Presentation thumbnail
Similarities and differences between aortic stenosis with normal left ventricular systolic function and heart failure with preserved ejection fraction
Doctor N. De Biase (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
The Endothelial Activation and Stress Index (EASIX) in heart failure with preserved ejection fraction - getting to the bottom of endothelial dysfunction as a central paradigm in heart failure
Doctor V. Zach (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Perception of heart failure with preserved ejection fraction by experienced cardiologists in Belgium
Doctor C. Georges (BE)
Abstract Slides Video
Presentation thumbnail
Characteristics and outcomes of patients with heart failure with preserved ejection fraction referred to a nurse led community heart failure clinic
Miss S. Tavares (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - pathophysiology and mechanisms 12

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Treatment of diastolic dysfunction by targeting beta-adrenergic receptors in vivo in a murine model of cardiometabolic HFpEF
thumbnail
Congress Presentation
Effects of sacubitril-valsartan alone or in combination with dapagliflozin on aging-related heart failure with preserved ejection fraction
thumbnail
Congress Presentation
Effects of empagliflozin on cardio-renal interaction in heart failure with reduced ejection fraction: results from in-vivo experiments and the CINNAMON-study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources